Skip to main content
Download PDF
  • Research article
  • Open access
  • Published:

Features of biliary tract diseases in ketamine abusers: a systematic review of case reports

Journal of Medical Case Reports volume 18, Article number: 84 (2024) Cite this article

Abstract

Background and aims

Anesthesiologists prefer ketamine for certain surgeries due to its effectiveness as a non-competitive inhibitor of the N-methyl-D-aspartate receptor in the brain. Recently, this agent has also shown promise as an antidepressant. However, ketamine can cause hallucinogenic effects and is sometimes abused as an illicit drug. Ketamine abuse has been associated with liver and bile duct complications. This systematic study aims to better understand cholangiopathy in ketamine abusers by reviewing case reports.

Methods and material

In this systematic review, a comprehensive literature search was conducted with the terms “biliary tract diseases” and “ketamine”. Case reports and case series of adult patients with documented ketamine abuse and reported cholangiopathy or biliary tract disease were included. We extracted the data of relevant information and the results were reported through narrative synthesis and descriptive statistics.

Results

A total of 48 studies were initially identified, and 11 studies were finally included in the review. The mean age of the patients was 25.88 years. Of the 17 patients, 64.7% were men. Symptoms often included abdominal pain, nausea, and vomiting. Most patients were discharged with improved symptoms and liver function. Common bile duct dilation and other findings were observed in imaging results and other diagnostic studies.

Conclusion

This review highlights the diverse presentations and diagnostic modalities used in ketamine-induced cholangiography. These patients tend to be young men with deranged liver function tests and abdominal pain, which should be taken into consideration. These patients often require a multidisciplinary approach in their management.

Peer Review reports

Introduction

Ketamine is a synthetic phencyclidine derivative with both analgesic and anesthetic properties [1]. It has a molecular weight of 237.72 g/mol and its pKa is about 7.5 [2]. Its onset of action is within 30 seconds of intravenous administration and it has a half-life of 2.5 hours [3]. Ketamine is metabolized by liver through N-demethylation and hydroxylation, which is in turn excreted into urine (90%) and bile (10%) [4]. This substance acts as an antagonist on N-methyl-D-aspartate (NMDA) receptors and noncompetitively blocks glutamate [5].

Anesthesiologists favor ketamine over other agents for certain surgical procedures, and this medication has been widely used for this purpose since its discovery in 1962 [6]. It has also been used as an antidepressant in recent years and has shown promising results [7]. However, ketamine can also exert hallucinogenic effects, vivid imagery, and short-term excitement, and is used as an illicit drug via oral or inhalation routes [8].

Ketamine medical use has been associated with hepatobiliary complications, which is well established in the literature [9, 10]. Burned patients who receive large accumulative doses of ketamine are more prone to develop these complication [11, 12]. Recently, critically ill patients with coronavirus disease 2019 (COVID-19) have also been afflicted with biliary tract diseases such as secondary sclerosing cholangitis [13]. Moreover, similar to burned patients, ketamine abusers who consume large quantities of the drug are susceptible to biliary tract disease [14].

Despite its rarity, there are multiple case reports that address cholangiopathy in ketamine abusers. However, to the best of our knowledge, there is no methodological study that presents the findings of these case reports to give us a better understanding of this complication. Thus, the present systematic review of case reports is designed to better characterize the features of cholangiopathy in ketamine abusers.

Method

Literature search and eligibility criteria

We used the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guideline to conduct the present systematic review. We carried out a thorough literature search in PubMed, Google Scholar, and Web of Science using the Medical Subject Headings (MeSH) terms “biliary tract diseases” and “ketamine” from inception until October 2023. The full search terms are outlined in the appendix. We did not limit the preliminary search results with any filters. Furthermore, to avoid missing any pertinent article, we hand-searched the references of each selected study. The diagram explaining the selection process is depicted in Fig. 1. Studies were included if they met the following inclusion criteria: (1) were case reports or case series of adult patients aged 18 years or older, (2) patients with documented ketamine abuse, (3) patients with reported cholangiopathy or biliary tract disease, and (4) were written in English language. The following were excluded: (1) non-adult patients, (2) reports with etiologies other than ketamine abuse, such as respiratory distress syndrome, and (3) patients with other confirmed hepatobiliary conditions such as viral hepatitis and cirrhosis.

Fig. 1
figure 1

PRISMA flow diagram for study selection

Full size image

Selection of studies

The studies retrieved by the initial search were examined independently by two reviewers (AT and HN). As the first step, we identified the duplicates and removed them. The search results were then truncated to case reports (could be published as letter, correspondence, commentary, and so on) with at least one patient developing cholangiopathy following ketamine administration. Afterward, each paper was evaluated for eligibility on the basis of title, abstract, and full text. If a full-text article was unavailable, the correspondent was contacted for a copy, and in case of disagreement between the reviewers, a decision was made by consensus or by consulting a third reviewer (AN). The selected studies contained information about diagnosis, laboratory tests and imaging, demographics (for example, age and sex), liver function tests, and the outcomes of the disease.

Data extraction and quality assessment

We extracted the following items after the final selection: study region and year, demographics of patients, past medical history, presenting signs and symptoms, liver function test results, ketamine abuse pattern and duration, imaging findings (for example, ultrasound and magnetic resonance imaging), biopsy and cytology findings, treatment approach, and outcome of the disease (that is,. deceased or discharged). To minimize the effect of biases, we assessed the quality of each included study with a standardized tool [15]. A narrative synthesis was used to report the results and descriptive statistics were used to calculate the frequency and percentage for categorical variables, as well as mean and standard deviation for continuous variables.

Results

Study characteristics and patients’ clinical information

Overall, 48 studies (PubMed = 19, Web of Science = 29) were identified through our initial search, of which 4 were duplicates and removed. A total of 33 studies were excluded on the basis of title and abstract, and finally 11 studies were included in this review [16,17,18,19,20,21,22,23,24,25,26]. The study selection process is outlined in Fig. 1. Studies were conducted from 2009 through 2020 in the UK [5], China [2], Hong Kong [3], and the USA [1]. Mean age was 25.88 ± 4.95 years, ranging from 18 to 38 years. Of the 17 patients, 11 (64.7%) were men and 6 were women. We found that three patients were concurrent alcohol abusers and two patients were human immunodeficiency virus (HIV) positive. Urinary tract infection (UTI) was observed in three patients, and two patients had a history of acute renal failure (ARF). A total of 15 patients presented with epigastric or right upper quadrant abdominal pain, along with other signs and symptoms such as nausea, vomiting, and fever. As for the other two patients, one of them was referred because of deranged liver function tests and the other had urinary symptoms. Jaundice and hepatomegaly were detected in one patient.

Liver function tests (LFTs) were not reported for one patient and two patients had normal LFT. The initial alanine aminotransferase (ALT) levels were available for 11 patients, with a calculated mean of 232.09 ± 148.14 IU/L, ranging from 75 to 521 IU/L. These patients had been abusing ketamine for 3 months to 15 years (median 2 years). Of 17 patients, 9 received endoscopic retrograde cholangiopancreatography (ERCP) for treatment, and other treatment approaches included drug rehabilitation program, catheterization, biliary drainage, and conservative therapy. Except for one patient who lacked outcome information, all patients were discharged with improved symptoms and LFT results.

Imaging results and other diagnostic studies

The main imaging modalities that were used across the studies were ultrasound (US), magnetic resonance cholangiopancreatography (MRCP), computed tomography (CT), and hepatobiliary iminodiacetic acid (HIDA) scan, which were utilized in 13, 9, 10, and 3 patients, respectively. In addition, the findings of ERCP, which is mainly a therapeutic approach, were reported in five patients. Common bile duct (CBD) dilation was visualized in 12 patients. The investigators detected strictures in three patients and gallstone in one patient. HIDA scan showed diminished gall bladder ejection fraction in one patient and was normal in the other two patients. Other diagnostic studies, including brush cytology, colonoscopy, and biopsies, were performed in a subgroup of nine patients. These findings are all summarized in Table 1.

Table 1 Summary of study characteristics and patients’ demographic, clinical, and imaging information
Full size table

Discussion

This study provides valuable information about the characteristics of patients who presented with ketamine-induced cholangiopathy. The mean age of the patients was 25.88 ± 4.95 years, with a range from 18 to 38 years. Men accounted for 64.7% of the patients, while women accounting for the remaining 35.3%. Additionally, three patients were found to be alcohol abusers and two were HIV positive. Among the patients, three had UTIs and two had a history of ARF. The epidemiology of other biliary diseases, such as primary sclerosing cholangitis with a 2:1 male to female ratio, is comparable to our results [27]. The patients involved in this review were rather young, which can be explained by the recreational nature of the ketamine abuse. Concomitant alcohol abuse is quite common in ketamine abuser population and can be up to 25% [28]. Due to the possible cytotoxic effect of ketamine on urothelium, patients often experience urinary symptoms [29]. This explains the resurgence of urinary symptoms in the patients included in this review.

The most common presenting symptom was epigastric or right upper quadrant abdominal pain, which was reported by 15 patients and also witnessed in clinical practice. Two other patients either presented with deranged liver function tests or urinary symptoms. LFTs were available for all but one patient, with two patients having normal LFT results. The initial ALT was measured in 11 patients, with a mean value of 232.09 ± 148.14 IU/L, ranging from 75 to 521 IU/L. The upper limit of normal value (ULN) for ALT is 30 IU/L in men and 19 IU/L in women [30]. The reported ALT levels in this review are more than twice the ULN and should be considered pathologic and require more workup [31]. It is suggested that ketamine hepatotoxicity can result in LFT derangements similar to that of drug-induced liver injury [32]. This effect can be augmented via inhibiting CYP32A enzyme, which is a hepatic enzyme responsible for ketamine breakdown [33], and is also demonstrated by an animal study [34].

The duration of ketamine abuse ranged from 3 months to 15 years, with a median of 2 years. The therapeutic dose for ketamine varies depending on its indication. Anesthesia, pain management, and depression require a dose of 1 mg/kg, 0.4 mg/kg, and 0.5 mg/kg, respectively [35,36,37]. The consumed ketamine dose in this review is patient-reported and was up to 3 g per day, which is substantially higher than the accumulated therapeutic dose at first glance, which is held responsible for causing hepatobiliary disturbances in this population. In the current review, all patients except one, who lacked outcome information, were discharged with improved symptoms and LFT results. This is in contrast with the disease outcome in ketamine-induced cholangiopathy in critically ill patients, which had a significant mortality rate [38]. This can be explained by the fact that the patients in this review did not have any underlying liver pathology and they were not in critical condition.

Imaging studies played a crucial role in the diagnosis and assessment of patients. The preferred method to visualize biliary tree was MRCP [39]. Specifically, in the current review, 13 patients underwent ultrasound, 9 underwent MRCP, 10 underwent CT, and 3 underwent HIDA scans. In our study, HIDA revealed diminished gall bladder ejection fraction in one patient indicative of functional gallbladder dysfunction [40], while two patients had normal results. The most common imaging finding was common bile duct (CBD) dilation, observed in 12 patients. Similar to the results of this review, a retrospective study showed that CBD dilation in ketamine-induced cholangiopathy can be found in up to 69% of patients [41].

The growing bulk of evidence regarding the etiology of these complications is not consistent. At a molecular level, ketamine can potentially contribute to biliary tract dilation by affecting NMDA receptors on smooth muscle cells [42]. Additionally, increased glutamate and NMDA concentration in dorsal motor nucleus of vagus nerve seem to increase gallbladder motility, which can be potentially antagonized by ketamine [20]. This may, in turn, lead to strictures in biliary tract, chronic inflammation, and fibrosis [21]. These conjectures of direct toxicity of ketamine are supported by several studies that were carried out to evaluate ketamine’s effect on urinary system [43, 44]. An animal study by Thune et al. suggests that ketamine stimulates opiate receptors and is associated with an increase in flow resistance through the sphincter of Oddi [45]. On the contrary, the results of sphincter of Oddi manometry in human subjects receiving low-dose ketamine for endoscopy does not support this claim [46].

This retrospective review was subject to several limitations. Due to the anecdotal nature of case reports, we could not draw robust conclusions. We used narrative synthesis for the most part and could not perform a meta-analysis due to the obvious heterogeneity. In addition, the number of patients who were selected was considerably low and several of them lacked relevant clinical data or were of low quality. We did not include retrospective observational studies that did not contain the details on individual patients. In spite of these limitations, this review used a systematic approach and endeavored to summarize the characteristics of biliary tract diseases in ketamine abusers.

Conclusion

The current review provides important clinical information regarding the characteristics of patients with ketamine-induced cholangiopathy. These patients tend to be young men with deranged LFT and abdominal pain. Our study also highlights the diverse presentations and diagnostic modalities used in assessing these patients, emphasizing the importance of a multidisciplinary approach in their management.

Availability of data and materials

All the data regarding this manuscript is provided within the main document.

References

  1. Lodge D, Mercier M. Ketamine and phencyclidine: the good, the bad and the unexpected. Br J Pharmacol. 2015;172(17):4254–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. PubChem. Bethesda (MD): National Library of Medicine (US), National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 3821, Ketamine. https://pubchem.ncbi.nlm.nih.gov/compound/Ketamine 2004.

  3. Adamowicz P, Kala M. Urinary excretion rates of ketamine and norketamine following therapeutic ketamine administration: method and detection window considerations. J Anal Toxicol. 2005;29(5):376–82.

    Article  CAS  PubMed  Google Scholar 

  4. Haas DA, Harper DG. Ketamine: a review of its pharmacologic properties and use in ambulatory anesthesia. Anesth Prog. 1992;39(3):61.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Zhang Y, Ye F, Zhang T, Lv S, Zhou L, Du D, et al. Structural basis of ketamine action on human NMDA receptors. Nature. 2021;596(7871):301–5.

    Article  CAS  PubMed  ADS  Google Scholar 

  6. Peltoniemi MA, Hagelberg NM, Olkkola KT, Saari TI. Ketamine: a review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy. Clin Pharmacokinet. 2016;55:1059–77.

    Article  CAS  PubMed  Google Scholar 

  7. Coyle CM, Laws KR. The use of ketamine as an antidepressant: a systematic review and meta-analysis. Hum Psychopharmacol Clin Exp. 2015;30(3):152–63.

    Article  CAS  Google Scholar 

  8. Le TT, Cordero IP, Jawad MY, Swainson J, Di Vincenzo JD, Jaberi S, et al. The abuse liability of ketamine: a scoping review of preclinical and clinical studies. J Psychiatr Res. 2022;151:476–96.

    Article  PubMed  Google Scholar 

  9. Wai M, Chan W, Zhang A, Wu Y, Yew D. Long-term ketamine and ketamine plus alcohol treatments produced damages in liver and kidney. Hum Exp Toxicol. 2012;31(9):877–86.

    Article  CAS  PubMed  Google Scholar 

  10. Wong GL-H, Tam Y-H, Ng C-F, Chan AW-H, Choi PC-L, Chu WC-W, et al. Liver injury is common among chronic abusers of ketamine. Clin Gastroenterol Hepatol. 2014;12(10):1759-62. e1.

    Article  CAS  PubMed  Google Scholar 

  11. Ben-Ari Z, Levingston D, Weitzman E, Haviv-Yadid Y, Cohen-Ezra O, Weiss P, et al. Secondary sclerosing cholangitis following major burn. Ann Hepatol. 2015;14(5):695–701.

    Article  CAS  PubMed  Google Scholar 

  12. Deniau B, Mallet V, de Tymowski C, Dépret F. Ketamine-based analgosedation for dressing changes in burn patients. Eur J Anaesthesiol EJA. 2022;39(10):845–6.

    Article  Google Scholar 

  13. Meersseman P, Blondeel J, De Vlieger G, van der Merwe S, Monbaliu D. Secondary sclerosing cholangitis: an emerging complication in critically ill COVID-19 patients. Intensive Care Med. 2021;47(9):1037–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Seto W-K, Mak S-K, Chiu K, Vardhanabhuti V, Wong H-F, Leong H-T, et al. Magnetic resonance cholangiogram patterns and clinical profiles of ketamine-related cholangiopathy in drug users. J Hepatol. 2018;69(1):121–8.

    Article  CAS  PubMed  Google Scholar 

  15. Murad MH, Sultan S, Haffar S, Bazerbachi F. Methodological quality and synthesis of case series and case reports. BMJ Evidence-Based Med. 2018. https://0-doi-org.brum.beds.ac.uk/10.1136/bmjebm-2017-110853.

    Article  Google Scholar 

  16. Al-Nowfal A, Al-Abed YA. Chronic biliary colic associated with ketamine abuse. Int Med Case Rep J. 2016;23:135–7.

    Google Scholar 

  17. Aslam SP, Cacciottolo TM, Bowden D, Griffiths WJ, Godfrey EM. An unusual cause of cholangiopathy. Gastrointest Endosc. 2019;90(5):850–1.

    Article  PubMed  Google Scholar 

  18. Cheung T, Poon R, Chan A, Lo C. Education and Imaging. Hepatobiliary and pancreatic: cholangiopathy in ketamine user--an emerging new condition. J Gastroenterol Hepatol. 2014; 29(9):1663-.

  19. Gutkin E, Hussain SA, Kim SH. Ketamine-induced biliary dilatation: from Hong Kong to New York. J Addict Med. 2012;6(1):89–91.

    Article  CAS  PubMed  Google Scholar 

  20. Lo R, Krishnamoorthy R, Freeman J, Austin A. Cholestasis and biliary dilatation associated with chronic ketamine abuse: a case series. 2011.

  21. Lui K, Lee W, Li M. Ketamine-induced cholangiopathy. Hong Kong Med J. 2014;20(78):e1-2.

    Google Scholar 

  22. Nyirenda TJ, Shirazi-Nejad A, Soliman AS, Shirazi-Nejad AR. Persistent ketamine-induced cholangiopathy: an approach to management. Cureus. 2020. https://0-doi-org.brum.beds.ac.uk/10.7759/cureus.11611.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Seto W-K, Ng M, Chan P, Ng IO-L, Cheung SC-W, Hung IF-N, et al. Ketamine-induced cholangiopathy: a case report. Official journal of the American College of Gastroenterology| ACG. 2011; 106(5):1004–5.

  24. Turkish A, Luo JJ, Lefkowitch JH. Ketamine abuse, biliary tract disease, and secondary sclerosing cholangitis. Hepatology. 2013;58(2):825–7.

    Article  PubMed  Google Scholar 

  25. Wong S, Lee K, Wong J, Ng W, Cheung Y, Lai P. Dilated common bile ducts mimicking choledochal cysts in ketamine abusers. Hong Kong Med J. 2009;15(1):53–6.

    CAS  PubMed  Google Scholar 

  26. Zhou J, Shaw SG, Gilleece Y. Dilated common bile duct and deranged liver function tests associated with ketamine use in two HIV-positive MSM. Int J STD AIDS. 2013;24(8):667–9.

    Article  PubMed  Google Scholar 

  27. Gochanour E, Jayasekera C, Kowdley K. Primary sclerosing cholangitis: epidemiology, genetics, diagnosis, and current management. Clin Liver Dis. 2020;15(3):125.

    Article  Google Scholar 

  28. Kobayashi NHC, Farias SV, Luz DA, Machado-Ferraro KM, Conceição BCd, Silveira CCMd, et al. Ketamine plus alcohol: what we know and what we can expect about this. Int J Mol Sci. 2022;23(14):7800.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Winstock AR, Mitcheson L, Gillatt DA, Cottrell AM. The prevalence and natural history of urinary symptoms among recreational ketamine users. BJU Int. 2012;110(11):1762.

    Article  PubMed  Google Scholar 

  30. Prati D, Taioli E, Zanella A, Torre ED, Butelli S, Del Vecchio E, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137(1):1–10.

    Article  CAS  PubMed  Google Scholar 

  31. Lee TH, Kim WR, Poterucha JJ. Evaluation of elevated liver enzymes. Clin Liver Dis. 2012;16(2):183–98.

    Article  PubMed  PubMed Central  Google Scholar 

  32. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012.

  33. Chu PS, Kwok S, Lam K, Chu T, Chan SW, Man C, et al. Street ketamine’-associated bladder dysfunction: a report of ten cases. Hong Kong Med J. 2007;13(4):311.

    PubMed  Google Scholar 

  34. Chan W-H, Sun W-Z, Ueng T-H. Induction of rat hepatic cytochrome P-450 by ketamine and its toxicological implications. J Toxicol Environ Health A. 2005;68(17–18):1581–97.

    Article  CAS  PubMed  Google Scholar 

  35. Andrade C. Ketamine for depression, 4: in what dose, at what rate, by what route, for how long, and at what frequency? J Clin Psychiatry. 2017;78(7):10106.

    Article  Google Scholar 

  36. Marland S, Ellerton J, Andolfatto G, Strapazzon G, Thomassen O, Brandner B, et al. Ketamine: use in anesthesia. CNS Neurosci Ther. 2013;19(6):381–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Visser E, Schug S. The role of ketamine in pain management. Biomed Pharmacother. 2006;60(7):341–8.

    Article  CAS  PubMed  Google Scholar 

  38. Bartoli A, Cursaro C, Seferi H, Andreone P. Secondary sclerosing cholangitis after SARS-CoV2: ICU ketamine use or virus-specific biliary tropism and injury in the context of biliary ischemia in critically ill patients? Hepatic Medicine: Evidence and Research. 2023:93–112.

  39. Soto JA, Castrillon G. Gallbladder and biliary tree imaging techniques. In: Hamm B, Ros PR, editors. Abdominal imaging. Berlin, Heidelberg: Springer, Berlin Heidelberg; 2013. p. 1229–40.

    Chapter  Google Scholar 

  40. Goussous N, Maqsood H, Spiegler E, Kowdley GC, Cunningham SC. HIDA scan for functional gallbladder disorder: ensure that you know how the scan was done. Hepatobiliary Pancreat Dis Int. 2017;16(2):197–201.

    Article  PubMed  Google Scholar 

  41. Yu W-L, Cho CC-M, Lung PF-C, Hung EH-Y, Hui JW-Y, Chau HH-L, et al. Ketamine-related cholangiopathy: a retrospective study on clinical and imaging findings. Abdominal Imaging. 2014;39:1241–6.

    Article  PubMed  Google Scholar 

  42. Hottat A, Hantson P. Toxicity patterns associated with chronic ketamine exposure. Toxicologie Analytique et Clinique. 2023. https://0-doi-org.brum.beds.ac.uk/10.1016/j.toxac.2023.02.001.

    Article  Google Scholar 

  43. Colebunders B, Van Erps P. Cystitis due to the use of ketamine as a recreational drug: a case report. J Med Case Reports. 2008;2:1–3.

    Article  Google Scholar 

  44. Shahani R, Streutker C, Dickson B, Stewart RJ. Ketamine-associated ulcerative cystitis: a new clinical entity. Urology. 2007;69(5):810–2.

    Article  PubMed  Google Scholar 

  45. Thune A, Jivegård L, Pollard H, Moreau J, Schwartz J, Svanvik J. Location of enkephalinase and functional effects of [Leu5] enkephalin and inhibition of enkephalinase in the feline main pancreatic and bile duct sphincters. Clin Sci. 1992;82(2):169–73.

    Article  CAS  Google Scholar 

  46. Varadarajulu S, Tamhane A, Wilcox CM. Prospective evaluation of adjunctive ketamine on sphincter of Oddi motility in humans. J Gastroenterol Hepatol. 2008;23(8pt2):e405–9.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

None.

Funding

No funding was received for this work.

Author information

Authors and Affiliations

  1. Department of Surgery, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

    Alireza Teymouri

  2. Faculty of Pharmacy, Tehran Medical Science, Islamic Azad University, Tehran, Iran

    Hadis Nasoori

  3. Department of Physical Medicine and Rehabilitation, School of Medicine, Shiraz University of Medical Sciences, Zand St., Shiraz, 71348-14336, Iran

    Maryamsadat Fakheri & Aref Nasiri

Authors
  1. Alireza Teymouri
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hadis Nasoori
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maryamsadat Fakheri
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Aref Nasiri
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

AT designed the study and performed the initial search in the databases. AT and HN reviewed the retrieved articles and screened them on the basis of eligibility criteria. MSF synthesized the data and wrote the results section. AT and AN wrote the manuscript and edited the final version. AN supervised the whole process and validated the ultimate article.

Corresponding author

Correspondence to Aref Nasiri.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

None.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Appendix

Appendix

Full search terms

((("secondary sclerosing cholangitis"[Title/Abstract] AND "case reports"[Publication Type]) OR ("cholestatic liver injury"[Title/Abstract] AND "case reports"[Publication Type]) OR ("biliary"[Title/Abstract] AND "case reports"[Publication Type]) OR ("Biliary Tract Diseases"[MeSH Terms] AND "case reports"[Publication Type]) OR ("Cholangitis"[MeSH Terms] AND "case reports"[Publication Type]) OR ("hepatobiliary disease"[Title/Abstract] AND "case reports"[Publication Type]) OR ("biliary dilatation"[Title/Abstract] AND "case reports"[Publication Type]) OR ("cholestasis"[Title/Abstract] AND "case reports"[Publication Type]) OR ("cholangitis, sclerosing"[MeSH Terms] AND "case reports"[Publication Type])) AND "case reports"[Publication Type] AND (("Ketamine"[Title/Abstract] OR "Ketamine"[MeSH Terms]) AND "case reports"[Publication Type])) AND (casereports[Filter]).

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Teymouri, A., Nasoori, H., Fakheri, M. et al. Features of biliary tract diseases in ketamine abusers: a systematic review of case reports. J Med Case Reports 18, 84 (2024). https://0-doi-org.brum.beds.ac.uk/10.1186/s13256-024-04421-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://0-doi-org.brum.beds.ac.uk/10.1186/s13256-024-04421-6

Keywords

Journal of Medical Case Reports

ISSN: 1752-1947